These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23282017)

  • 1. X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).
    Hummer AA; Heffeter P; Berger W; Filipits M; Batchelor D; Büchel GE; Jakupec MA; Keppler BK; Rompel A
    J Med Chem; 2013 Feb; 56(3):1182-96. PubMed ID: 23282017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
    Bijelic A; Theiner S; Keppler BK; Rompel A
    J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
    Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
    J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
    Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
    Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
    Hartinger CG; Jakupec MA; Zorbas-Seifried S; Groessl M; Egger A; Berger W; Zorbas H; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Oct; 5(10):2140-2155. PubMed ID: 18972504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
    Hartinger CG; Zorbas-Seifried S; Jakupec MA; Kynast B; Zorbas H; Keppler BK
    J Inorg Biochem; 2006 May; 100(5-6):891-904. PubMed ID: 16603249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
    Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
    J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
    Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
    Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.
    Schluga P; Hartinger CG; Egger A; Reisner E; Galanski MS; Jakupec MA; Keppler BK
    Dalton Trans; 2006 Apr; (14):1796-802. PubMed ID: 16568190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of multiwalled carbon nanotubes with a ruthenium drug candidate-indazolium[tetrachlorobis(1
    Richert M; Trykowski G; Walczyk M; Cieślak MJ; Kaźmierczak-Barańska J; Królewska-Golińska K; Sobczak JW; Biniak S
    Dalton Trans; 2020 Dec; 49(46):16791-16800. PubMed ID: 33174575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
    Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
    Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.
    Stultz LK; Hunsucker A; Middleton S; Grovenstein E; O'Leary J; Blatt E; Miller M; Mobley J; Hanson PK
    Metallomics; 2020 Jun; 12(6):876-890. PubMed ID: 32329475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2].
    Büchel GE; Stepanenko IN; Hejl M; Jakupec MA; Keppler BK; Arion VB
    Inorg Chem; 2011 Aug; 50(16):7690-7. PubMed ID: 21739939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.
    Henke MM; Richly H; Drescher A; Grubert M; Alex D; Thyssen D; Jaehde U; Scheulen ME; Hilger RA
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):58-60. PubMed ID: 19203540
    [No Abstract]   [Full Text] [Related]  

  • 20. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
    Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.